Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Phase 3 Completed 71 enrolled International Medical Center of Japan Ministry of Health, Labour and Welfare, Japan · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A selection study in treatment naive HIV patients to compare the virologic success rate of once daily antiretroviral treatment regimens at the 48th week with Epzicom(lamivudine and abacavir) plus efavirenz and Epzicom plus ritonavir boosted atazanavir. The superior regimen will be hired to the comparative study to the current first line regimen (tenofovir plus lamivudine plus efavirenz)

Timeline

Start: 2005-09
Primary completion: 2009-09
Completion: 2009-09

Publications

Results Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S; Japanese Anti-HIV-1 QD Therapy Study Group. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. Intern Med. 2011;50(7):699-705. doi: 10.2169/internalmedicine.50.4572. Epub 2011 Apr 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atazanavir	Other / unclassified	300 mg	—
Comparator	Efavirenz	Other / unclassified	300 mg	—
Background	Raltegravir	Other / unclassified	—	—
Background	Ritonavir	Other / unclassified	100 mg	—

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Summary

Timeline

Publications

Drugs

Indications